Lance Alstodt - Sep 15, 2023 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role: President, CEO, COB, Director, 10%+ Owner
Signature: /s/ Lance Alstodt
Stock symbol: BRTX
Transactions as of: Sep 15, 2023
Transactions value $: $3,740
Form type: 4
Date filed: 9/18/2023, 09:17 AM
Previous filing: Sep 13, 2023
Next filing: Feb 15, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BRTX	Common Stock	Purchase	$3.74K	+2.2K	+1.17%	$1.70	190K	Sep 15, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BRTX	Stock Option						293K	Sep 15, 2023	Common Stock	293K	$5.08	Direct	F3
holding	BRTX	Stock Option						42.1K	Sep 15, 2023	Common Stock	42.1K	$5.08	Direct	F4
holding	BRTX	Stock Option						107K	Sep 15, 2023	Common Stock	107K	$2.91	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed in multiple trades at prices ranging from $1.66 to $1.75 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
F2	Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024.
F3	The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F4	The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested.
F5	The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.